Abstracts tagged "Diagnosis and giant cell arteritis"

Abstract Number: 891 • 2016 ACR/ARHP Annual Meeting
Clinal Characterisitics and Diagnosis of Patients with Negative Temporal Artery Biopsy and without a Final Diagnosis of Giant Cell Arteritis
Kim Heang Ly¹, Alexis Regent², Eric Liozon¹, Matthieu Groh², Guillaume Gondran¹, Claire Le Jeunne³, Antoine Brezin⁴, Pierre-Yves Robert⁵, Jean-Louis Bourges⁶, Philippe Bertin⁷, Anne-Laure Fauchais¹ and Luc Mouthon³, ¹Internal Medicine, University Hospital of Limoges, Limoges, France, ²National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ³Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ⁴Ophtalmology, Cochin Hospital, Paris, France, ⁵Ophthalmology, University Hospital of Limoges, Limoges, France, ⁶Ophthalmology, Cochin Hospital, Paris, France, ⁷Rheumatology, University Hospital of Limoges, Limoges, France
Background/Purpose: To describe the characteristics and diagnosis of patients with negative temporal artery biopsy (TAB) for whom a final diagnosis of giant cell arteritis (GCA)…
Abstract Number: 2361 • 2012 ACR/ARHP Annual Meeting
Misdiagnosis of Giant Cell Arteritis Presenting As Fever of Unknown Origin
Chiara Stagnaro¹, Rosaria Talarico², Claudia Ferrari², Anna d'Ascanio³ and Stefano Bombardieri⁴, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²University of Pisa, Rheumatology Unit, Pisa, Italy, ³Department of Internal Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy, ⁴Department of Clinical and Experimental Medicine, Rheumatology Unit, University of Pisa, Pisa, Italy
Background/Purpose: Giant cell arteritis (GCA) represents the most common primary vasculitis of the elderly, that usually involves large and medium sized arteries. The wide spectrum…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].